.png){kind=icon}
.png){kind=icon}
Return
First Approval of Semaglutide for MASH in India: A Paradigm Shift in MASLD Management?
.png){kind=icon}
PRE
AI
D
M
DOI：10.1016/j.drudis.2026.104762.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Semaglutide improves MASH and reduces liver fibrosis. • India approves semaglutide for the treatment of MASH. • Semaglutide is the second approved pharmacotherapy for MASLD in India after saroglitazar. • Large-scale clinical trials are warranted to evaluate semaglutide in the Indian population.
Journal
IF:
7.5
Papers:
6.3K
Citations:
2.3W
Organization
No organization information available
Cited Papers